

PAUL A. BROWN, M.D.  
Chairman of the Board

30 October 1981

Joseph J. Zavertnik, M.D.  
The Florida Cancer Council  
Chairman Committee  
Unproven Treatment  
Methods  
25 S.E. Second Avenue  
Miami, Florida 33131

Dear Dr. Zavertnik:

This letter is in response to your letter, dated October 19, 1981, relating to the "I.A.T." treatment for cancer advocated by Dr. Burton.

On July 16, 1979, MetPath entered into an agreement with Dr. Burton pursuant to which Dr. Burton was to share with MetPath certain information regarding his test for cancer and grant to MetPath a license to utilize such information to develop therefrom and market a commercially viable cancer test.

The first phase of our protocol was to verify the existence and determine the measurability of the substance in serum said by Dr. Burton to be related to the presence or absence of cancer. Secondly, we proposed to develop a commercially viable technique to measure this substance. The third phase of our protocol was to perform a limited analysis on 3,000 to 5,000 patients known to have cancer and to determine the level of correlation between the results of the Burton test and the clinical condition of the patients. The fourth and final phase of the protocol was to perform a blind study involving 10,000 patients.

Based upon our evaluation of the information furnished to us by Dr. Burton and extensive laboratory testing, we have concluded that there exists a substance in serum the level of which is related to the presence or absence of malignant carcinoma. We were, however, unable to develop a sufficiently reliable technique to measure or identify this substance. In fact, we obtained 25% false positives in tests of patients known to be free of cancer and 25% false negatives on patients known to have cancer.



Joseph J. Zavertrnik, M.D.  
30 October 1981  
Page 2

Based upon our inability to discover a sufficiently reliable test, we were not able to proceed with phases three and four of our protocol, and accordingly, our agreement with Dr. Burton was terminated in December 1980.


As you can see, the "MetPath contract" was a means by which MetPath could work with Dr. Burton with a view to determining the validity and/or reproducibility of his research and developing a commercially viable test for cancer. Notwithstanding Dr. Burton's assertions to the contrary, our contract was not "another practical validation of the principles upon which I.A.T. is based".

MetPath did, in fact, send a certain number of vials of blood samples to Dr. Burton in the Bahamas for testing. The results obtained by Dr. Burton were substantially delayed and were not received by MetPath until well after the original specimens had been destroyed. Accordingly, no conclusion can be drawn from the results of this testing trial. We are not aware of the basis for the assertion that the results were "spectacular" or that the "tests proved to be 100% accurate and identified the blood specimens of patients known to have cancer".

Because MetPath was not able to develop a cancer testing technique based upon Dr. Burton's methodology which was sufficiently reliable, the contract with Dr. Burton was terminated. MetPath no longer has any relationship with Dr. Burton, and accordingly, MetPath has no plans to market the Burton test.

We are quite distressed at the assertions being made by Dr. Burton and hope that this letter will put any misconceptions to rest.

Very truly yours,



Paul A. Brown, M.D.

PAB/dt